- Report
- May 2024
- 128 Pages
Global
From €2729EUR$2,999USD£2,330GBP
€3638EUR$3,999USD£3,107GBP
- Report
- September 2022
- 120 Pages
Global
From €2275EUR$2,500USD£1,943GBP
- Report
- February 2024
- 120 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- February 2024
- 125 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- February 2024
- 120 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- April 2023
- 115 Pages
Global
From €4322EUR$4,750USD£3,691GBP
- Report
- May 2023
- 140 Pages
Global
From €4503EUR$4,949USD£3,846GBP
- Report
- July 2024
- 154 Pages
Global
From €3093EUR$3,400USD£2,642GBP
€3867EUR$4,250USD£3,302GBP
- Clinical Trials
- April 2025
- 3092 Pages
Global
From €3139EUR$3,450USD£2,681GBP
- Drug Pipelines
- February 2023
- 127 Pages
Global
From €13643EUR$14,995USD£11,652GBP
- Report
- February 2023
- 32 Pages
Global
From €3635EUR$3,995USD£3,104GBP
- Report
- March 2025
- 210 Pages
Global
From €4544EUR$4,995USD£3,881GBP
- Report
- May 2024
- 292 Pages
Global
From €4544EUR$4,995USD£3,881GBP
- Report
- December 2023
- 182 Pages
Global
€4544EUR$4,995USD£3,881GBP
- Report
- May 2024
- 116 Pages
Global
From €3594EUR$3,950USD£3,069GBP
- Report
- March 2026
- 338 Pages
Canada
From €4413EUR$4,850USD£3,769GBP
- Report
- March 2026
- 156 Pages
China
From €4413EUR$4,850USD£3,769GBP
- Report
- March 2026
- 174 Pages
Germany
From €4413EUR$4,850USD£3,769GBP
- Report
- March 2026
- 192 Pages
India
From €4413EUR$4,850USD£3,769GBP
- Report
- February 2026
- 150 Pages
Canada
From €4413EUR$4,850USD£3,769GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more